Glaucoma is the second leading cause of blindness in the world affecting approximately 70 million people. Glaucoma can occur at any age but the commonest type occurs in middle to old age. The disease has a genetic basis and can be inherited. As a result we have been studying the genetics of the disease in two large families from Tasmania. We hope to identify the genes involved in disease causation using a number of genetic techniques. Once mutations in a disease gene have been identified from af ....Glaucoma is the second leading cause of blindness in the world affecting approximately 70 million people. Glaucoma can occur at any age but the commonest type occurs in middle to old age. The disease has a genetic basis and can be inherited. As a result we have been studying the genetics of the disease in two large families from Tasmania. We hope to identify the genes involved in disease causation using a number of genetic techniques. Once mutations in a disease gene have been identified from affected individuals we will then be in a position to look for mutations in other family members and identify those individuals at risk of developing disease. Improvements in our understanding of how these genes are involved in disease causation will allow us to offer diagnostic testing to the wider community and develop better therapeutic interventions for treatment.Read moreRead less
Identifying Target Genes For Novel Anti-epileptic Therapies In The Mouse
Funder
National Health and Medical Research Council
Funding Amount
$469,802.00
Summary
Epilepsy is a disease which affects 2-4% of the population. There are a wide range of drugs available to treat the condition but there is consistently 30-40% of patients who do not respond well to any of these drugs and who continue to have seizures. The reason that there are no drugs available for these people is that most of the drugs available have been designed along the same principles. A new set of principles is needed to develop new drugs which will be able to treat those people not respo ....Epilepsy is a disease which affects 2-4% of the population. There are a wide range of drugs available to treat the condition but there is consistently 30-40% of patients who do not respond well to any of these drugs and who continue to have seizures. The reason that there are no drugs available for these people is that most of the drugs available have been designed along the same principles. A new set of principles is needed to develop new drugs which will be able to treat those people not responding to current therapy. This project is designed to identify new biologic pathways which may be interrupted with drugs to prevent seizures in people with epilepsy. This project uses a procedure to induce mutations into genes in mice and then screens for mice which do not seize when challenged with a drug which generates seizures in mice. Genetic studies will identify the mutated genes and these will be used as potential targets for new therapies or will identify new biological pathway which should expand the use of future anti-epileptic drugs.Read moreRead less
Estimation of non-additive genetic variance for complex traits using genome-wide single nucleotide polymorphyisms and sequence data. Finding genes for traits of importance in agriculture, ecology and human health depends on understanding the genetic basis of these traits. This project will investigate whether variation in traits in humans, cattle and wild sheep are influenced by gene-gene interactions.
The genetic architecture and evolution of quantitative traits. Most important traits are controlled by many genes and by the environment, however there is little knowledge of how many genes are involved in these complex traits and what their effects are. This project will describe the number of genes and their effects for complex traits in humans and livestock and explain how these genes evolve.
Improving Rehabilitation Outcomes Through Self-Management: My Therapy
Funder
National Health and Medical Research Council
Funding Amount
$743,438.00
Summary
We must ensure patients have enough therapy practice for the best inpatient rehabilitation outcomes. During rehabilitation, we know patients don't often receive enough therapy and actually spend most of the day sitting and lying down. My Therapy was designed to increase independent practice of therapy exercises during rehabilitation, in addition to usual care, without additional staff. Through My Therapy, patients achieved 100 extra minutes of weekly therapy participation and better function.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE180100073
Funder
Australian Research Council
Funding Amount
$468,474.00
Summary
Nanoimprint systems: expanding research capability of roll to roll printer. This project aims to strengthen Australian research activities in the development of advanced multifunctional materials through the purchase of thermal and ultraviolet (UV) nano-imprint lithography modules to expand the nanofabrication capacity of roll-to-roll printer line. The various processes used to make nano-sized devices and components fall into two major categories, coating and patterning. Integrating the thermal ....Nanoimprint systems: expanding research capability of roll to roll printer. This project aims to strengthen Australian research activities in the development of advanced multifunctional materials through the purchase of thermal and ultraviolet (UV) nano-imprint lithography modules to expand the nanofabrication capacity of roll-to-roll printer line. The various processes used to make nano-sized devices and components fall into two major categories, coating and patterning. Integrating the thermal and UV nanoimprint lithography modules into the roll-to-roll printer line will provide a unique and simple materials fabrication platform. It will combine coating and nanolithography processes in a low cost, high-throughput and high-resolution format for advanced nanofabrication of microelectronic, telecommunication, biomedical and energy devices.Read moreRead less